Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 2/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL3415729 | 1.00 | PRCP (0.34) | PRCPSLC6A2SLC6A4SLC6A3ADH1A | |
| Ethane SCHEMBL28373914 | 0.89 | — | — | |
| SCHEMBL475385 | 0.89 | — | — | |
| SCHEMBL80843 | 0.89 | — | — | |
| SCHEMBL2267946 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL28298516 | 0.86 | — | — | |
| SCHEMBL28164332 | 0.84 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3679748 | 0.81 | — | — | |
| SCHEMBL4955062 | 0.81 | — | — | |
| SCHEMBL348693 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993018045-A1 | ANTI-CANCER PYRROLOBENZODIAZEPINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-09-16 | — | — | WO | claimed |
| US-7704924-B2 | Library of compounds comprising pyrrolobenzodiazepine moieties | SPIROGEN LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| EP-1107969-B1 | COLLECTIONS OF COMPOUNDS | SPIROGEN LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20040092736-A1 | Collections of compounds | SPIROGEN LIMITED | 2004-05-13 | — | — | US | disclosed |
| US-6660856-B2 | A group of potent, naturally occurring anti-tumor antibiotics produced by Streptomyces species | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2003-12-09 | — | — | US | disclosed |
| US-20030195196-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-20030187253-A1 | SYNTHESIS OF PYRROLO[2,1-C][1,4]BENZODIAZEPINE ANALOGUES | KAOHSIUNG MEDICAL UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| US-6608192-B1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-08-19 | — | — | US | disclosed |
| EP-1109811-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6562806-B1 | A prodrug may be converted into an antitumour agent under the influence of an enzyme that is linked to a monoclonal antibody so that it can bind to a tumour associated antigen | SPIROGEN LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |
| EP-1109811-A2 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2001-06-27 | — | — | EP | disclosed |
| EP-1107969-A2 | COLLECTIONS OF COMPOUNDS | Spirogen Limited (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012506-A2 | COLLECTIONS OF COMPOUNDS | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012507-A2 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-1993018045-A1 | ANTI-CANCER PYRROLOBENZODIAZEPINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187253-A1 | SYNTHESIS OF PYRROLO[2,1-C][1,4]BENZODIAZEPINE ANALOGUES | GABRA4, GABRP, GABRD | PRCP 3111/4885SLC6A2 3810/4885SLC6A4 1710/4885 |
| US-20030195196-A1 | Pyrrolobenzodiazepines | CNR2, CNR1, HRH3 | PRCP 1776/4885SLC6A2 255/4885SLC6A4 880/4885 |
| US-20040092736-A1 | Collections of compounds | CBR3, CYCS, CBR1 | PRCP 3790/4885SLC6A2 1243/4885SLC6A4 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.